Novo Nordisk's FREHEMGO Gets Positive CHMP Opinion For Haemophilia A

Novo Nordisk said the European Medicines Agency's CHMP issued a positive opinion recommending marketing authorization for FREHEMGO (denecimig) to treat haemophilia A, including patients with or without inhibitors. The recommendation is a key regulatory step toward potential European commercialization, although final European Commission approval remains pending.